TY - JOUR
T1 - Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers
T2 - A randomized, placebo-controlled, double-blind trial
AU - Kotzailias, Nicole
AU - Andonovski, Toni
AU - Dukic, Alexander
AU - Serebruany, Victor L.
AU - Jilma, Bernd
PY - 2006/4
Y1 - 2006/4
N2 - Depression is associated with an increased incidence of vascular events and develops after stroke and myocardial infarction. Beside potential clinical outcome benefits of selective serotonin reuptake inhibitors for vascular diseases, bleeding events were reported. We investigated whether paroxetine and aspirin synergistically inhibit platelet function. Paroxetine (20 mg/d) was administered over 18 days to 20 men in a randomized, placebo-controlled, crossover design. Aspirin (100 mg/d) was coadministered within the last 4 study days. Platelet function was assessed by the platelet function analyzer and by flow cytometry. Paroxetine prolonged epinephrine-dependent predictive index within 14 days (P <.02). Aspirin enhanced the predictive index (P <.004 vs baseline and P > .05 between periods). A trend toward decreased thrombin receptor-activating peptide-induced CD62P expression after paroxetine was further enhanced by aspirin treatment (P > .05 between periods). The combination of paroxetine and aspirin did not further inhibit platelet plug formation under high shear stress in male smokers.
AB - Depression is associated with an increased incidence of vascular events and develops after stroke and myocardial infarction. Beside potential clinical outcome benefits of selective serotonin reuptake inhibitors for vascular diseases, bleeding events were reported. We investigated whether paroxetine and aspirin synergistically inhibit platelet function. Paroxetine (20 mg/d) was administered over 18 days to 20 men in a randomized, placebo-controlled, crossover design. Aspirin (100 mg/d) was coadministered within the last 4 study days. Platelet function was assessed by the platelet function analyzer and by flow cytometry. Paroxetine prolonged epinephrine-dependent predictive index within 14 days (P <.02). Aspirin enhanced the predictive index (P <.004 vs baseline and P > .05 between periods). A trend toward decreased thrombin receptor-activating peptide-induced CD62P expression after paroxetine was further enhanced by aspirin treatment (P > .05 between periods). The combination of paroxetine and aspirin did not further inhibit platelet plug formation under high shear stress in male smokers.
KW - Aspirin
KW - Platelet function
KW - Platelet function analyzer (PFA-100)
KW - Randomized controlled trial
KW - Selective serotonin reuptake inhibitor (SSRI)
UR - http://www.scopus.com/inward/record.url?scp=33644979767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644979767&partnerID=8YFLogxK
U2 - 10.1177/0091270006286432
DO - 10.1177/0091270006286432
M3 - Article
C2 - 16554456
AN - SCOPUS:33644979767
VL - 46
SP - 468
EP - 475
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
SN - 0091-2700
IS - 4
ER -